Gasior Maciej, Witkin Jeffrey M, Goldberg Steven R, Munzar Patrik
Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, MSC: 1408, Building 10, Room 5N250, Bethesda, MD 20892-1408, USA.
Eur J Pharmacol. 2004 Jun 28;494(2-3):183-9. doi: 10.1016/j.ejphar.2004.05.011.
Chlormethiazole is a positive modulator of gamma-aminobutyric acid (GABA)(A) receptors used in the treatment of alcohol withdrawal seizures. It recently has been reported to attenuate seizures engendered by acute and repeated exposure to cocaine in mice and neurotoxic effects of methamphetamine in rats. The aim of the present study was to determine whether chlormethiazole could also attenuate the discriminative stimulus effects of methamphetamine, a behavior predictive of the subjective effects of methamphetamine in humans. In Sprague-Dawley rats trained to discriminate 1.0 mg/kg methamphetamine [intraperitoneally (i.p.)] from saline under a fixed-ratio schedule of food delivery, the ability of chlormethiazole (i.p.) to (1) substitute for methamphetamine, (2) antagonize effects of methamphetamine and to (3) shift the methamphetamine dose-effect function was investigated. Chlormethiazole (18 and 30 mg/kg, i.p.) partially substituted for the discriminative stimulus effects of methamphetamine when administered alone (maximum group average, 60% responses on the methamphetamine-appropriate lever). Chlormethiazole did not attenuate effects of methamphetamine when coadministered with the training dose of methamphetamine. Instead, chlormethiazole potentiated the discriminative stimulus effects of methamphetamine as demonstrated by a significant (about 2.5-fold) leftward and upward shift in the methamphetamine dose-effect function in the presence of chlormethiazole (10 mg/kg). In conclusion, the present findings suggest that there is a behavioral interaction between methamphetamine and chlormethiazole. The profile of this interaction is qualitatively different from that of methamphetamine and classical GABAergic drugs (i.e., benzodiazepines and barbiturates), suggesting the involvement of non-GABAergic mechanisms in the effects produced by chlormethiazole.
氯美噻唑是一种γ-氨基丁酸(GABA)(A)受体的正向调节剂,用于治疗酒精戒断性癫痫发作。最近有报道称,它可减轻小鼠急性和反复接触可卡因引发的癫痫发作以及大鼠甲基苯丙胺的神经毒性作用。本研究的目的是确定氯美噻唑是否也能减轻甲基苯丙胺的辨别刺激效应,这种行为可预测甲基苯丙胺对人类的主观效应。在斯普拉格-道利大鼠中,按照固定比例进食计划训练它们区分腹腔注射(i.p.)1.0 mg/kg甲基苯丙胺和生理盐水,研究了氯美噻唑(i.p.)(1)替代甲基苯丙胺、(2)拮抗甲基苯丙胺效应以及(3)改变甲基苯丙胺剂量-效应函数的能力。单独给药时,氯美噻唑(18和30 mg/kg,i.p.)部分替代了甲基苯丙胺的辨别刺激效应(最大组平均水平为在甲基苯丙胺对应杠杆上有60%的反应)。与甲基苯丙胺训练剂量共同给药时,氯美噻唑并未减轻甲基苯丙胺的效应。相反,氯美噻唑增强了甲基苯丙胺的辨别刺激效应,如在存在氯美噻唑(10 mg/kg)时,甲基苯丙胺剂量-效应函数显著向左上方移动(约2.5倍)所示。总之,目前的研究结果表明甲基苯丙胺和氯美噻唑之间存在行为相互作用。这种相互作用的特征在性质上与甲基苯丙胺和经典GABA能药物(即苯二氮䓬类和巴比妥类药物)不同,这表明氯美噻唑产生的效应涉及非GABA能机制。